Radiolabelling and preclinical characterisation of [
4-1BB
ATG-101
PD-L1
PET
Zirconium-89
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
11 May 2024
11 May 2024
Historique:
received:
14
11
2023
accepted:
26
04
2024
medline:
11
5
2024
pubmed:
11
5
2024
entrez:
10
5
2024
Statut:
aheadofprint
Résumé
ATG-101, a bispecific antibody that simultaneously targets the immune checkpoint PD-L1 and the costimulatory receptor 4-1BB, activates exhausted T cells upon PD-L1 crosslinking. Previous studies demonstrated promising anti-tumour efficacy of ATG-101 in preclinical models. Here, we labelled ATG-101 with ATG-101, anti-PD-L1, and an isotype control were conjugated with p-SCN-Deferoxamine (Df). The Df-conjugated antibodies were radiolabelled with The Df-conjugation and [ [
Identifiants
pubmed: 38730087
doi: 10.1007/s00259-024-06742-6
pii: 10.1007/s00259-024-06742-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Wykes MN, Lewin SR. Immune checkpoint blockade in infectious diseases. Nat Rev Immunol. 2018;18:91–104. https://doi.org/10.1038/nri.2017.112 .
doi: 10.1038/nri.2017.112
pubmed: 28990586
Powles T, Plimack ER, Soulières D, Waddell T, Stus V, Gafanov R, et al. Pembrolizumab plus Axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020;21:1563–73. https://doi.org/10.1016/s1470-2045(20)30436-8 .
doi: 10.1016/s1470-2045(20)30436-8
pubmed: 33284113
Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30:405–11. https://doi.org/10.1093/annonc/mdy518 .
doi: 10.1093/annonc/mdy518
pubmed: 30475947
Vafaei S, Zekiy AO, Khanamir RA, Zaman BA, Ghayourvahdat A, Azimizonuzi H, et al. Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier. Cancer Cell Int. 2022;22:2. https://doi.org/10.1186/s12935-021-02407-8 .
doi: 10.1186/s12935-021-02407-8
pubmed: 34980128
pmcid: 8725311
Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016;7:10501. https://doi.org/10.1038/ncomms10501 .
doi: 10.1038/ncomms10501
pubmed: 26883990
pmcid: 4757784
Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010;107:4275–80. https://doi.org/10.1073/pnas.0915174107 .
doi: 10.1073/pnas.0915174107
pubmed: 20160101
pmcid: 2840093
Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 2017;23:551–5. https://doi.org/10.1038/nm.4308 .
doi: 10.1038/nm.4308
pubmed: 28346412
pmcid: 5466900
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-year survival with combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019;381:1535–46. https://doi.org/10.1056/NEJMoa1910836 .
doi: 10.1056/NEJMoa1910836
pubmed: 31562797
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or Monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34. https://doi.org/10.1056/NEJMoa1504030 .
doi: 10.1056/NEJMoa1504030
pubmed: 26027431
pmcid: 5698905
Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Reviews Clin Oncol. 2016;13:473–86. https://doi.org/10.1038/nrclinonc.2016.58 .
doi: 10.1038/nrclinonc.2016.58
Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob J-J, Cowey CL, et al. Overall survival with combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2017;377:1345–56. https://doi.org/10.1056/NEJMoa1709684 .
doi: 10.1056/NEJMoa1709684
pubmed: 28889792
pmcid: 5706778
Dahlén E, Veitonmäki N, Norlén P. Bispecific antibodies in cancer immunotherapy. Therapeutic Adv Vaccines Immunotherapy. 2018;6:3–17. https://doi.org/10.1177/2515135518763280 .
doi: 10.1177/2515135518763280
Kim KM, Kim HW, Kim JO, Baek KM, Kim JG, Kang CY. Induction of 4-1BB (CD137) expression by DNA damaging agents in human T lymphocytes. Immunology. 2002;107:472–9. https://doi.org/10.1046/j.1365-2567.2002.01538.x .
doi: 10.1046/j.1365-2567.2002.01538.x
pubmed: 12460192
pmcid: 1782822
Sanchez-Paulete AR, Labiano S, Rodriguez-Ruiz ME, Azpilikueta A, Etxeberria I, Bolaños E, et al. Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy. Eur J Immunol. 2016;46:513–22. https://doi.org/10.1002/eji.201445388 .
doi: 10.1002/eji.201445388
pubmed: 26773716
Sabbagh L, Pulle G, Liu Y, Tsitsikov EN, Watts TH. ERK-Dependent Bim Modulation downstream of the 4-1BB-TRAF1 Signaling Axis is a critical mediator of CD8 T cell survival in Vivo1. J Immunol. 2008;180:8093–101. https://doi.org/10.4049/jimmunol.180.12.8093 .
doi: 10.4049/jimmunol.180.12.8093
pubmed: 18523273
Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellström KE, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med. 1997;3:682–5. https://doi.org/10.1038/nm0697-682 .
doi: 10.1038/nm0697-682
pubmed: 9176498
Gauttier V, Judor JP, Le Guen V, Cany J, Ferry N, Conchon S. Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer. Int J Cancer. 2014;135:2857–67. https://doi.org/10.1002/ijc.28943 .
doi: 10.1002/ijc.28943
pubmed: 24789574
Segal NH, He AR, Doi T, Levy R, Bhatia S, Pishvaian MJ, et al. Phase I study of single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in patients with Advanced Cancer. Clin Cancer Res. 2018;24:1816–23. https://doi.org/10.1158/1078-0432.Ccr-17-1922 .
doi: 10.1158/1078-0432.Ccr-17-1922
pubmed: 29549159
Segal NH, Logan TF, Hodi FS, McDermott D, Melero I, Hamid O, et al. Results from an Integrated Safety Analysis of Urelumab, an agonist Anti-CD137 monoclonal antibody. Clin Cancer Res. 2017;23:1929–36. https://doi.org/10.1158/1078-0432.Ccr-16-1272 .
doi: 10.1158/1078-0432.Ccr-16-1272
pubmed: 27756788
You G, Lee Y, Kang YW, Park HW, Park K, Kim H, et al. B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8(+) tumor-infiltrating lymphocytes. Sci Adv. 2021;7. https://doi.org/10.1126/sciadv.aax3160 .
Song MY, Lee E-J, Chung H, Lee Y, Park YB, Jee MH, et al. Abstract 6524: a novel HER2/4-1BB bispecific antibody, YH32367 (ABL105) shows potent anti-tumor effect through tumor-directed T cell activation. Cancer Res. 2020;80:6524. https://doi.org/10.1158/1538-7445.Am2020-6524 .
doi: 10.1158/1538-7445.Am2020-6524
Qu QX, Zhu XY, Du WW, Wang HB, Shen Y, Zhu YB, et al. 4-1BB Agonism Combined with PD-L1 Blockade increases the number of tissue-resident CD8 + T cells and facilitates Tumor Abrogation. Front Immunol. 2020;11:577. https://doi.org/10.3389/fimmu.2020.00577 .
doi: 10.3389/fimmu.2020.00577
pubmed: 32391001
pmcid: 7193033
Wang Y, Zhang X, Xu C, Nan Y, Fan J, Zeng X, et al. Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphoma. Front Immunol. 2022;13:1004475. https://doi.org/10.3389/fimmu.2022.1004475 .
doi: 10.3389/fimmu.2022.1004475
pubmed: 36544785
pmcid: 9762552
Yuwen H, Li T, Ren Y, Hoenemann D, Mei J, Shan B, et al. 893 ATG-101, a novel PD-L1/4–1BB bispecific antibody, augments anti-tumor immunity through immune checkpoint inhibition and PDL1-directed 4–1BB activation. J Immunother Cancer. 2021;9:A936–7. https://doi.org/10.1136/jitc-2021-SITC2021.893 .
doi: 10.1136/jitc-2021-SITC2021.893
Burvenich IJG, Goh YW, Guo N, Gan HK, Rigopoulos A, Cao D, et al. Radiolabelling and preclinical characterization of (89)Zr-Df-radiolabelled bispecific anti-PD-L1/TGF-βRII fusion protein bintrafusp alfa. Eur J Nucl Med Mol Imaging. 2021;48:3075–88. https://doi.org/10.1007/s00259-021-05251-0 .
doi: 10.1007/s00259-021-05251-0
pubmed: 33608805
Wichmann CW, Poniger S, Guo N, Roselt P, Rudd SE, Donnelly PS, et al. Automated radiosynthesis of [89Zr]Zr-DFOSq-Durvalumab for imaging of PD-L1 expressing tumours in vivo. Nucl Med Biol. 2023;120–121:108351. https://doi.org/10.1016/j.nucmedbio.2023.108351 .
doi: 10.1016/j.nucmedbio.2023.108351
pubmed: 37224789
Parakh S, Lee ST, Gan HK, Scott AM. Radiolabeled antibodies for Cancer Imaging and Therapy. Cancers. 2022;14:1454.
doi: 10.3390/cancers14061454
pubmed: 35326605
pmcid: 8946248
Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, et al.
doi: 10.1038/s41591-018-0255-8
pubmed: 30478423
Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984;72:77–89. https://doi.org/10.1016/0022-1759(84)90435-6 .
doi: 10.1016/0022-1759(84)90435-6
pubmed: 6086763
Zheng Y, Fang YC, Li J. PD-L1 expression levels on tumor cells affect their immunosuppressive activity. Oncol Lett. 2019;18:5399–407. https://doi.org/10.3892/ol.2019.10903 .
doi: 10.3892/ol.2019.10903
pubmed: 31612048
pmcid: 6781757
Lin G, Fan X, Zhu W, Huang C, Zhuang W, Xu H, et al. Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer. Oncotarget. 2017;8:83986–94. https://doi.org/10.18632/oncotarget.20233 .
doi: 10.18632/oncotarget.20233
pubmed: 29137398
pmcid: 5663570
Darga EP, Dolce EM, Fang F, Kidwell KM, Gersch CL, Kregel S, et al. PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer. PLoS ONE. 2021;16:e0260124. https://doi.org/10.1371/journal.pone.0260124 .
doi: 10.1371/journal.pone.0260124
pubmed: 34780566
pmcid: 8592410
Rom-Jurek E-M, Kirchhammer N, Ugocsai P, Ortmann O, Wege AK, Brockhoff G. Regulation of programmed death Ligand 1 (PD-L1) expression in breast Cancer cell lines in Vitro and in Immunodeficient and Humanized Tumor mice. Int J Mol Sci. 2018;19:563.
doi: 10.3390/ijms19020563
pubmed: 29438316
pmcid: 5855785
Zhang R, Yang Y, Dong W, Lin M, He J, Zhang X et al. D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1. Proceedings of the National Academy of Sciences. 2022;119:e2114851119. doi: https://doi.org/10.1073/pnas.2114851119 .
Josefsson A, Nedrow JR, Park S, Banerjee SR, Rittenbach A, Jammes F, et al. Imaging, Biodistribution, and Dosimetry of Radionuclide-labeled PD-L1 antibody in an Immunocompetent mouse model of breast Cancer. Cancer Res. 2016;76:472–9. https://doi.org/10.1158/0008-5472.Can-15-2141 .
doi: 10.1158/0008-5472.Can-15-2141
pubmed: 26554829
Chatterjee S, Lesniak WG, Gabrielson M, Lisok A, Wharram B, Sysa-Shah P, et al. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. Oncotarget. 2016;7:10215–27. https://doi.org/10.18632/oncotarget.7143 .
doi: 10.18632/oncotarget.7143
pubmed: 26848870
pmcid: 4891115
Giesen D, Broer LN, Lub-de Hooge MN, Popova I, Howng B, Nguyen M, et al. Probody Therapeutic Design of 89Zr-CX-072 promotes Accumulation in PD-L1–Expressing tumors compared to normal murine lymphoid tissue. Clin Cancer Res. 2020;26:3999–4009. https://doi.org/10.1158/1078-0432.Ccr-19-3137 .
doi: 10.1158/1078-0432.Ccr-19-3137
pubmed: 31953313
Abou DS, Ku T, Smith-Jones PM. In vivo biodistribution and accumulation of 89Zr in mice. Nucl Med Biol. 2011;38:675–81. https://doi.org/10.1016/j.nucmedbio.2010.12.011 .
doi: 10.1016/j.nucmedbio.2010.12.011
pubmed: 21718943
pmcid: 4527328
Krache A, Fontan C, Pestourie C, Bardiès M, Bouvet Y, Payoux P, et al. Preclinical pharmacokinetics and Dosimetry of an 89Zr labelled Anti-PDL1 in an Orthotopic Lung Cancer Murine Model. Front Med. 2022;8. https://doi.org/10.3389/fmed.2021.741855 .
Latvala S, Jacobsen B, Otteneder MB, Herrmann A, Kronenberg S. Distribution of FcRn Across Species and tissues. J Histochem Cytochem. 2017;65:321–33. https://doi.org/10.1369/0022155417705095 .
doi: 10.1369/0022155417705095
pubmed: 28402755
pmcid: 5625855
van den Hoff J, Oehme L, Schramm G, Maus J, Lougovski A, Petr J, et al. The PET-derived tumor-to-blood standard uptake ratio (SUR) is superior to tumor SUV as a surrogate parameter of the metabolic rate of FDG. EJNMMI Res. 2013;3:77. https://doi.org/10.1186/2191-219x-3-77 .
doi: 10.1186/2191-219x-3-77
pubmed: 24267032
pmcid: 4175513
Hofheinz F, Hoff Jvd, Steffen IG, Lougovski A, Ego K, Amthauer H, et al. Comparative evaluation of SUV, tumor-to-blood standard uptake ratio (SUR), and dual time point measurements for assessment of the metabolic uptake rate in FDG PET. EJNMMI Res. 2016;6:53. https://doi.org/10.1186/s13550-016-0208-5 .
doi: 10.1186/s13550-016-0208-5
pubmed: 27334609
pmcid: 4917506
Nedrow JR, Josefsson A, Park S, Ranka S, Roy S, Sgouros G. Imaging of programmed cell death Ligand 1: impact of protein concentration on distribution of Anti-PD-L1 SPECT agents in an Immunocompetent Murine Model of Melanoma. J Nucl Med. 2017;58:1560–6. https://doi.org/10.2967/jnumed.117.193268 .
doi: 10.2967/jnumed.117.193268
pubmed: 28522738
pmcid: 5632734
Chi X, Luo S, Ye P, Hwang W-L, Cha J-H, Yan X, et al. T-cell exhaustion and stemness in antitumor immunity: characteristics, mechanisms, and implications. Front Immunol. 2023;14. https://doi.org/10.3389/fimmu.2023.1104771 .
Pichler AC, Carrié N, Cuisinier M, Ghazali S, Voisin A, Axisa PP, et al. TCR-independent CD137 (4-1BB) signaling promotes CD8(+)-exhausted T cell proliferation and terminal differentiation. Immunity. 2023;56:1631–e4810. https://doi.org/10.1016/j.immuni.2023.06.007 .
doi: 10.1016/j.immuni.2023.06.007
pubmed: 37392737
pmcid: 10649891
Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21:581–90. https://doi.org/10.1038/nm.3838 .
doi: 10.1038/nm.3838
pubmed: 25939063
pmcid: 4458184
Chester C, Sanmamed MF, Wang J, Melero I. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. Blood. 2018;131:49–57. https://doi.org/10.1182/blood-2017-06-741041 .
doi: 10.1182/blood-2017-06-741041
pubmed: 29118009
Wang J, Zhao W, Cheng L, Guo M, Li D, Li X, et al. CD137-Mediated pathogenesis from Chronic Hepatitis to Hepatocellular Carcinoma in Hepatitis B Virus-Transgenic mice. J Immunol. 2010;185:7654–62. https://doi.org/10.4049/jimmunol.1000927 .
doi: 10.4049/jimmunol.1000927
pubmed: 21059892
Hinner MJ, Aiba RSB, Jaquin TJ, Berger S, Dürr MC, Schlosser C, et al. Tumor-localized Costimulatory T-Cell Engagement by the 4-1BB/HER2 bispecific antibody-Anticalin Fusion PRS-343. Clin Cancer Res. 2019;25:5878–89. https://doi.org/10.1158/1078-0432.Ccr-18-3654 .
doi: 10.1158/1078-0432.Ccr-18-3654
pubmed: 31138587
Murphy R, Halford S, Symeonides SN. Project Optimus, an FDA initiative: considerations for cancer drug development internationally, from an academic perspective. Front Oncol. 2023;13:1144056. https://doi.org/10.3389/fonc.2023.1144056 .
doi: 10.3389/fonc.2023.1144056
pubmed: 36937434
pmcid: 10020863
Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Reviews Clin Oncol. 2021;18:345–62. https://doi.org/10.1038/s41571-021-00473-5 .
doi: 10.1038/s41571-021-00473-5
Twomey JD, Zhang B. Cancer Immunotherapy Update: FDA-Approved checkpoint inhibitors and Companion Diagnostics. Aaps j. 2021;23:39. https://doi.org/10.1208/s12248-021-00574-0 .
doi: 10.1208/s12248-021-00574-0
pubmed: 33677681
Lv G, Sun X, Qiu L, Sun Y, Li K, Liu Q, et al. PET imaging of Tumor PD-L1 expression with a highly specific nonblocking single-domain antibody. J Nucl Med. 2020;61:117–22. https://doi.org/10.2967/jnumed.119.226712 .
doi: 10.2967/jnumed.119.226712
pubmed: 31253743
pmcid: 6954462
Brown EL, DeWeerd RA, Zidel A, Pereira PMR. Preclinical antibody-PET imaging of PD-L1. Front Nuclear Med. 2022;2. https://doi.org/10.3389/fnume.2022.953202 .
Bouleau A, Nozach H, Dubois S, Kereselidze D, Chevaleyre C, Wang C-I, et al. Optimizing Immuno-PET Imaging of Tumor PD-L1 expression: pharmacokinetic, Biodistribution, and dosimetric comparisons of
doi: 10.2967/jnumed.121.262967
pubmed: 34933891
pmcid: 9364342
Jagoda EM, Vasalatiy O, Basuli F, Opina ACL, Williams MR, Wong K, et al. Immuno-PET imaging of the programmed cell Death-1 ligand (PD-L1) using a Zirconium-89 labeled therapeutic antibody, Avelumab. Mol Imaging. 2019;18:1536012119829986. https://doi.org/10.1177/1536012119829986 .
doi: 10.1177/1536012119829986
pubmed: 31044647
pmcid: 6498777
Li M, Ehlerding EB, Jiang D, Barnhart TE, Chen W, Cao T, et al. In vivo characterization of PD-L1 expression in breast cancer by immuno-PET with (89)Zr-labeled avelumab. Am J Transl Res. 2020;12:1862–72.
pubmed: 32509182
pmcid: 7270013